SG158133A1 - Method for reversing multiple resistance in animal cells - Google Patents
Method for reversing multiple resistance in animal cellsInfo
- Publication number
- SG158133A1 SG158133A1 SG200908280-1A SG2009082801A SG158133A1 SG 158133 A1 SG158133 A1 SG 158133A1 SG 2009082801 A SG2009082801 A SG 2009082801A SG 158133 A1 SG158133 A1 SG 158133A1
- Authority
- SG
- Singapore
- Prior art keywords
- animal cells
- multiple resistance
- reversing multiple
- reversing
- resistance
- Prior art date
Links
- 210000004102 animal cell Anatomy 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004063639 | 2004-12-31 | ||
US65108505P | 2005-02-08 | 2005-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG158133A1 true SG158133A1 (en) | 2010-01-29 |
Family
ID=36582063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200908280-1A SG158133A1 (en) | 2004-12-31 | 2006-01-02 | Method for reversing multiple resistance in animal cells |
Country Status (10)
Country | Link |
---|---|
US (4) | US20100310554A1 (fr) |
EP (1) | EP1831382B1 (fr) |
JP (1) | JP5584393B2 (fr) |
KR (1) | KR101527213B1 (fr) |
CN (1) | CN101128593B (fr) |
AU (1) | AU2006203736B2 (fr) |
CA (1) | CA2592699C (fr) |
MX (1) | MX2007008136A (fr) |
SG (1) | SG158133A1 (fr) |
WO (1) | WO2006070023A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060099178A1 (en) | 2002-05-27 | 2006-05-11 | Holm Per S | Novel use of adenoviruses and nucleic acids coding therefor |
US20070110719A1 (en) | 2003-11-14 | 2007-05-17 | Holm Per S | Novel use of adenoviruses and nucleic acids that code for said viruses |
CA2610360A1 (fr) * | 2004-12-31 | 2006-07-06 | Per Sonne Holm | Adenovirus a region e1 absente et leur utilisation |
US8691866B2 (en) | 2008-12-10 | 2014-04-08 | The General Hospital Corporation | HIF inhibitors and use thereof |
WO2013119880A1 (fr) * | 2012-02-07 | 2013-08-15 | Global Bio Therapeutics Usa, Inc. | Procédé compartimenté d'administration d'acide nucléique et ses compositions et utilisations |
KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
US10202568B2 (en) | 2013-08-12 | 2019-02-12 | Invivosciences Inc. | Automated cell culture system and method |
EP3390428B1 (fr) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus |
CN117384961A (zh) | 2016-02-23 | 2024-01-12 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
US10813957B2 (en) * | 2016-10-07 | 2020-10-27 | Miami University | Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
EP3610870A4 (fr) * | 2017-03-31 | 2020-12-09 | Ogata, Hisanobu | Procédé d'expansion d'un virus oncolytique et agent antitumoral |
EP3630959A4 (fr) * | 2017-05-24 | 2021-03-17 | EpicentRx, Inc. | Adénovirus anti-angiogénique |
CN109576231B (zh) | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
CN113774031B (zh) * | 2020-06-10 | 2024-04-02 | 广州恩宝生物医药科技有限公司 | 一种复制型人腺病毒及其应用 |
JPWO2023054671A1 (fr) * | 2021-09-30 | 2023-04-06 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU718772B2 (en) * | 1995-03-24 | 2000-04-20 | Genzyme Corporation | Adenovirus vectors for gene therapy |
WO1997032481A1 (fr) * | 1996-03-07 | 1997-09-12 | The Regents Of The University Of California | Adenovirus sans assistant et totalement defectif pour therapie genetique |
ES2180258T3 (es) * | 1998-07-07 | 2003-02-01 | Transgene Sa | Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes. |
AU2145300A (en) * | 1998-11-18 | 2000-06-05 | Canji, Inc. | Adenoviral vectors |
DE19929569A1 (de) * | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
DE10031122A1 (de) * | 1999-06-30 | 2001-03-22 | Max Delbrueck Centrum | Mittel zur Diagnose und Therapie maligner Erkrankungen |
US6955808B2 (en) * | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
WO2001028569A1 (fr) * | 1999-10-15 | 2001-04-26 | Canji, Inc. | Vecteurs cibles |
US7048920B2 (en) * | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
US20030095989A1 (en) * | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
JP4354814B2 (ja) * | 2001-09-29 | 2009-10-28 | ヨンセイ ユニバーシティ | 改善された疾患治療効果を有する組換えアデノウィルス及びそれを含む薬剤学的組成物 |
DE10150984A1 (de) * | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Verwendung des adenoviralen E2-late-Promotors |
ES2310247T3 (es) * | 2002-04-25 | 2009-01-01 | Crucell Holland B.V. | Vectores adenovirales estables y metodos de propagacion de los mismos. |
US20060099178A1 (en) * | 2002-05-27 | 2006-05-11 | Holm Per S | Novel use of adenoviruses and nucleic acids coding therefor |
JP4988199B2 (ja) * | 2002-10-15 | 2012-08-01 | ホルム,ペル・ゾンネ | 新規アデノウイルス、それをコードする核酸及びその使用 |
MXPA05004074A (es) * | 2002-10-15 | 2005-09-20 | Sonne Holm Per | Nuevos adenovirus, acidos nucleicos que los codifican y su uso. |
CA2522380A1 (fr) * | 2003-03-19 | 2004-09-30 | Isogenis, Inc. | Inhibition specifique du rejet d'allogreffe |
JP4871726B2 (ja) * | 2003-04-28 | 2012-02-08 | ナノシス・インク. | 超疎液性表面、その作製法及び用途 |
EP1689446B1 (fr) * | 2003-11-14 | 2015-01-07 | Per Sonne Holm | Adenovirus, acides nucleiques les codant et utilisations associees |
US20070110719A1 (en) * | 2003-11-14 | 2007-05-17 | Holm Per S | Novel use of adenoviruses and nucleic acids that code for said viruses |
CA2610360A1 (fr) * | 2004-12-31 | 2006-07-06 | Per Sonne Holm | Adenovirus a region e1 absente et leur utilisation |
US20070292396A1 (en) * | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
-
2006
- 2006-01-02 JP JP2007548837A patent/JP5584393B2/ja active Active
- 2006-01-02 EP EP06701440.7A patent/EP1831382B1/fr active Active
- 2006-01-02 CA CA2592699A patent/CA2592699C/fr active Active
- 2006-01-02 MX MX2007008136A patent/MX2007008136A/es active IP Right Grant
- 2006-01-02 WO PCT/EP2006/000009 patent/WO2006070023A2/fr active Application Filing
- 2006-01-02 KR KR1020077017703A patent/KR101527213B1/ko active IP Right Grant
- 2006-01-02 CN CN200680006399.8A patent/CN101128593B/zh active Active
- 2006-01-02 AU AU2006203736A patent/AU2006203736B2/en active Active
- 2006-01-02 SG SG200908280-1A patent/SG158133A1/en unknown
-
2009
- 2009-09-09 US US12/556,560 patent/US20100310554A1/en not_active Abandoned
-
2011
- 2011-06-28 US US13/170,395 patent/US20110286999A1/en not_active Abandoned
-
2017
- 2017-03-17 US US15/461,668 patent/US11369650B2/en active Active
-
2022
- 2022-05-24 US US17/752,436 patent/US20220339219A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2007008136A (es) | 2008-02-12 |
US20100310554A1 (en) | 2010-12-09 |
US20170252443A1 (en) | 2017-09-07 |
AU2006203736B2 (en) | 2012-03-29 |
JP2008526188A (ja) | 2008-07-24 |
CN101128593A (zh) | 2008-02-20 |
CA2592699A1 (fr) | 2006-07-06 |
US20110286999A1 (en) | 2011-11-24 |
US20220339219A1 (en) | 2022-10-27 |
US11369650B2 (en) | 2022-06-28 |
EP1831382B1 (fr) | 2023-01-18 |
CA2592699C (fr) | 2023-02-21 |
KR20070103412A (ko) | 2007-10-23 |
CN101128593B (zh) | 2014-09-03 |
AU2006203736A1 (en) | 2006-07-06 |
EP1831382A2 (fr) | 2007-09-12 |
JP5584393B2 (ja) | 2014-09-03 |
KR101527213B1 (ko) | 2015-06-09 |
WO2006070023A3 (fr) | 2006-09-21 |
WO2006070023A2 (fr) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG158133A1 (en) | Method for reversing multiple resistance in animal cells | |
CY1122522T1 (el) | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος | |
DE602005010109D1 (de) | 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten | |
AP2289A (en) | Microbial biocementation. | |
EP1891595A4 (fr) | Reseaux sociaux crees par l'utilisateur | |
DE602005022897D1 (de) | Piperidinylamino-thienoä2,3-dü-pyrimidinverbindungen | |
EA200900781A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды | |
GB2437009A (en) | Ranking system | |
CO6241120A2 (es) | (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS. | |
FI20045162A0 (fi) | Ryhmäviestintä viestinjärjestelmässä | |
NO20054053D0 (no) | Triazolforbindelser anvendbare i terapi. | |
MX2007002917A (es) | Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma. | |
MX2008001638A (es) | Metodo de espaciado de piel entumecida. | |
ATE556446T1 (de) | Batterieanoden | |
GB0413142D0 (en) | Improvements in, or relating to testing | |
BR8203451Y1 (pt) | disposição construtiva em copo descartável. | |
NL1026117A1 (nl) | Rolstoel. | |
AU2004906102A0 (en) | Softshu horseshoe Rev. I | |
ITFR20040018A1 (it) | Antislavina & i.s.m. | |
UA4341U (uk) | Літична суміш для проведення гібернації та гіпотермії | |
ES1056941Y (es) | Percha multiple. | |
AU2005900374A0 (en) | The fish hooka, new submission | |
NL1025973A1 (nl) | Hengsel. | |
ITTV20040062A1 (it) | Procedimento per l'ottenimento di tubazioni, in particolare per il contenimento di cavi. | |
GB0415035D0 (en) | C.s.v. |